Mr. Philippe Dubuc reports

THERATECHNOLOGIES RECEIVES UPDATE FROM FDA ON TESAMORELIN F8 SUPPLEMENTAL BIOLOGIC LICENSE APPLICATION

Theratechnologies Inc. has received correspondence from the United States Food and Drug Administration (FDA) regarding the company's supplemental biologics licence application (sBLA) for the F8 formulation of tesamorelin. The FDA has notified the company that it is continuing its review of the application beyond the Prescription Drug User Fee Act (PDUFA) goal date of Jan. 22, 2024. Further information will be provided in due course.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.